CSL Behring and Bayer Healthcare Agreed to Extend Agreement for Supply of Helixate® Recombinant Coagulation Factor
CSL Behring (5950871) has agreed with Bayer Healthcare (16159456) for the continuation of supply and distribution of Helixate® recombinant coagulation Factor VIII- an important therapy for hemophilia A treatment.
Under the extended contract:
- Bayer will continue to supply Helixate® recombinant coagulation Factor VIII to CSL Behring through 2017.
- Bayer was granted a license to intellectual property related to recombinant FVIII.
- The two companies settled outstanding litigation relating to the supply of recombinant Factor VIII.
Other terms of the settlement were not disclosed.
Find more details from the press release.
Comment Preview